Objective: We sought to evaluate neonatal hearing assessment by the otoacoustic emission (OAE) test in very low birth weight (VLBW) infants exposed to antenatal steroids.
Introduction
Antenatal corticosteroid therapy has become the standard of care to improve neonatal outcomes in pregnancies at risk of a preterm birth less than 34 completed weeks gestation. 1 Yet, questions regarding the possible negative impact of steroids in premature infants have not been completely addressed. In rodent and rabbit models, antenatal glucocorticoid treatments have striking effects on brain growth with a concerning negative impact on behavioral development. [2] [3] [4] [5] [6] To date, these findings have not been confirmed in humans.
Profound congenital hearing loss is associated with delayed language, learning and speech development. 7 Otoacoustic emission (OAE) testing is a routine and reproducible test used in many hospitals to screen newborns for hearing deficits. Otoacoustic emissions are produced by healthy ears in response to acoustic stimulation. They are considered to be epiphenomena, and by-products of the activity of the outer hair cells in the cochlea. OAEs are measured by presenting a series of very brief acoustic stimuli to the ear through a probe that is inserted in the outer third of the ear canal. OAEs are evidence of a vital sensory process arising in the cochlea. OAEs only occur in a normal cochlea with normal hearing. If there is damage to the outer hair cells producing hearing loss, then OAEs are not evoked. OAEs have a reported sensitivity of 95%, with a negative predictive value of 99% for identifying infants with hearing loss. 8 So far, no data have shown antenatal steroid exposure to have a negative or positive impact on neonatal hearing or development of the auditory pathways. Owing to their extreme prematurity, very low birth weight (VLBW) infants, less than 1500 g, have an increased rate of failing the OAE compared to term newborns. By focusing on these high-risk neonates, we sought to test the null hypothesis that antenatal steroids do not have an impact, positive or negative, on newborn hearing screens. Of secondary interest were other factors that could affect hearing test results, including intraventricular hemorrhage (IVH), bronchopulmonary dysplasia and neonatal sepsis.
Methods
After approval by the Christiana Hospital Institutional Review Board, we reviewed our neonatal database for all newborns with a birth weight <1500 g. All data were abstracted from the chart by trained reviewers. This contemporaneously maintained neonatal database is periodically checked for accuracy.
From the neonatal data set, we abstracted the following obstetrical and maternal information: maternal demographic characteristics, gestational age at delivery of the infant, use of steroid therapy, maternal age, presence of chorioamnionitis or preeclampsia, multiple gestation, preterm labor, preterm premature rupture of the membranes and mode of delivery. Additionally, we collected the following neonatal data: neonatal OAE test results, neonatal illness severity as quantified by the score for neonatal acute physiology, 9 IVH, birth weight, the need for mechanical ventilation, bronchopulmonary dysplasia and periventricular leukomalacia (PVL).
For the purpose of this study, IVH was classified using the definition of Papile et al. 10 Severe IVH was considered grade III to IV. Cystic PVL was diagnosed only in the presence of echolucent cysts in the periventricular white matter. Echodense lesions in the periventricular white matter, without subsequent cyst formation, were not classified as PVL unless there was subsequent formation of echolucent cysts. Infants with ventricular expansion were also not classified as having cystic PVL unless there was formation of echolucent periventricular cysts. Infants who developed cystic PVL after developing IVH were classified as having both IVH and cystic PVL.
Late-onset sepsis was defined as a positive blood culture beyond 72 h of life. Bronchopulmonary dysplasia was defined as an oxygen requirement at 28 days of life.
11 Clinical chorioamnionitis was diagnosed by the attending obstetrician in the presence of maternal fever, uterine tenderness or foul smelling fluid. Prolonged rupture of membranes was considered greater than 24 h duration. The best obstetrical estimate was used to classify gestational age. The modified Ballard exam was used as an estimate of gestational age only in the absence of obstetrical dating. 12 OAEs were performed on all infants prior to their discharge from the neonatal intensive care unit, and a test was labeled as 'pass' (both ears passed), 'fail' (both ears failed) or 'suspect' (defined as failure of one ear or unable to obtain). Infants who failed the OAE had a confirmatory test performed. We then evaluated the data for the impact of steroid therapy on newborn hearing screens. For this investigation, steroid therapy was defined as maternal exposure to either dexamethasone 6 mg i.m. given every 6 h for four doses or betamethasone 12 mg i.m. given as two doses 24 h apart. We divided patients into two groups, those who received a full course of antenatal steroids and those who were unexposed. Patients who received partial therapy or more than one course of steroids were excluded from the analysis.
Statistics
For the purposes of analysis, data were stratified by OAE test result. Only infants who failed or passed the exam were included in the evaluation. Infants with a partial exam or an inadequate exam were excluded. Multivariate analysis was performed with logistic regression to assess the effect of steroid exposure on OAE results and to control for confounding variables. Univariate analysis was performed with the use of Student's t-test, Mann-Whitney U-test and w 2 test, where appropriate. A P-value of <0.05 was considered statistically significant.
For our sample size of 643 infants in two unequal groups, this study was adequately powered to detect a 12% reduction in the rate of passed hearing exams due to steroid exposure (power ¼ 0.80, a ¼ 0.05).
Ethics
All patient information was analyzed retrospectively from Christiana Hospital's neonatal and perinatal databases. Patient information was de-identified and kept in a secure location, which was accessible only by certified study personnel.
Results
During the study period, approximately 68 000 births occurred at Christiana Hospital. Within this group, 703 infants qualified as very low birth weight (<1500 g). Newborn hearing screen results were available for all infants. Within our study cohort, 548 infants (78%) passed the exam, with 95 infants (14%) failing the OAE and 59 infants (8%) labeled as suspect. The infants labeled as suspect were excluded from further analysis. Of the 643 eligible cases, 449 (70%) were exposed to antenatal corticosteroids and 194 (30%) were unexposed. The incidence of a failed screen was not different between the two groups: 16% (n ¼ 32) failure in steroid unexposed versus 14% (n ¼ 63) failure in the steroid exposed group (P ¼ 0.45). Notably, our study was underpowered to determine statistical significance for a 2% improvement by exposure to steroids. An additional power calculation revealed a need for 5100 patients in each arm to achieve statistical significance (a ¼ 0.05, b ¼ 0.20) for such a small effect. Table 1 presents the univariate analysis stratified by test results. There was no difference in the antenatal steroid administration between infants who passed and infants who failed their hearing screen (P ¼ 0.43). The two groups did not differ by the following obstetrical factors: maternal age at delivery, history of preeclampsia, chorioamnionitis, preterm labor, multiple gestation, preterm premature rupture of the membranes or mode of delivery. Additionally, the presence of neonatal PVL was not associated with failed OAE results.
The mean gestational age at delivery for infants who passed the hearing screen test was greater compared to infants who failed the hearing screen. Similarly, infants who failed their hearing screen had lower birth weights and higher rate of other neonatal morbidities (for example, severe IVH and bronchopulmonary dysplasia) compared to infants who passed. Table 2 presents the multivariate analysis for failing the OAE. In this analysis, steroid exposure was not associated with a failed test (odds ratio 0.83; confidence interval 0.5-1.4). However, bronchopulmonary dysplasia and severe IVH remained independently associated with increased odds of a failed OAE after controlling for potentially confounding variables.
Discussion
In our population of VLBW infants, antenatal steroid therapy was not associated with any impact on routine hearing screening outcomes. As part of a routine screening, all newborns admitted to our intensive care unit have an OAE performed. Our data have important clinical implications, as steroids are routinely recommended for mothers delivering infants between 24 and 34 weeks gestation, a group at high risk for hearing loss. The National Institutes of Health published a consensus statement in August 2000 with the caveat of multiple courses of corticosteroid having potential deleterious effects on the developing neonate. 13 Such concern originates from animal studies demonstrating delayed myelination and cellular development of the central nervous system when antenatal corticosteroids are given repeatedly. [4] [5] [6] Given that myelination is delayed in animal models exposed to antenatal steroids, identifying whether antenatal exposure to corticosteroids effects deficits in auditory nerve maturation becomes an important question. A finding of permanent hearing loss in a newborn is associated with multiple neurodevelopmental delays, including language, speech and learning impairments. 7, 8 In this investigation, we sought to evaluate VLBW newborns for the impact of steroid exposure on newborn hearing screens. We chose this specific group due to their high rate of failing the OAE. If steroid exposure contributes to a failed or improved test result, then these findings should be highlighted in this cohort.
As steroids are known to reduce mortality and other morbidities such as respiratory distress and IVH, 1, 3, 8, 10, 11 our data are reassuring in showing no detrimental effect on newborn hearing screen. A recently published manuscript demonstrated similar findings: antenatal corticosteroids, whether single or multiple courses, were not associated with adverse effects on neonatal auditory nerve maturation in those born at 28 to 32 weeks gestation.
14 This study by Amin et al. was a retrospective comparison of auditory neural maturation in neonates exposed to single versus multiple courses. While a different test was used to assess neonatal hearing deficit (the auditory brain stem evoked response ), 15 Sanjiv et al. demonstrated no difference in identified hearing deficits in premature infants by number of steroid courses. Notably, their infants were delivered at later gestational ages and had higher birth weights than in our study. As previously mentioned, infants who are born at later gestations with higher birth weights have a lower incidence of failed hearing screens. In our cohort of 705 VLBW infants, we found no impact of a single course of antenatal steroid exposure on the incidence of a positive or negative screen by the OAE. Although cheaper than, and different from, the auditory brain stem evoked response, the OAE is an accepted, routine and reproducible screening test for hearing impairment, with a sensitivity of 95% and a negative predictive value of 99%. With regard to known morbidities of neonates born prematurely, we demonstrated other factors (for example, severe IVH and bronchopulmonary dysplasia) to be associated with a failed OAE. Additionally, neonates born at an earlier gestation were found to have a higher rate of failed OAE.
While this investigation did not find any impact of steroids on OAE results, we did find an association between a failed test and smaller, sicker newborns. Our study has a number of important In summary, our data show that a single course of antenatal steroids does not contribute to outcomes of routine hearing exams in VLBW infants. This information adds to the literature that supports the safety of this therapy for infants at risk of a preterm birth. 14 Author's disclosure: All of the authors state that they have no financial interests that would be viewed as a potential conflict of interest. Moreover, we report that the data contained in this study have not been presented in any other published format. These data were presented in abstract form at the 2006 annual clinical meeting of the Society of Maternal Fetal Medicine in Miami, FL, USA.
